AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

Pacemakers, implantable cardiac defibrillators (ICDs), and cardiac resynchronization
therapy (CRT) devices are lifesaving treatments for a number of cardiac conditions. Device …

Background The American College of Chest Physicians Clinical Practice Guideline on the
Perioperative Management of Antithrombotic Therapy addresses 43 Patients-Interventions …

Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy
devices are potentially life-saving treatments for a number of cardiac conditions, but are not …

A thrombin-like serine protease, jararassin-I, was isolated from the venom of Bothrops
jararaca. The protein was obtained in high yield and purity by a single chromatographic step …

Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …

While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation
(AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major …

Atrial fibrillation (AF) is an increasingly prevalent arrhythmia; its pathophysiology and
progression are well studied. Stroke and bleeding risk models have been created and …